KZR
Kezar Life Sciences, Inc.
Set alert
- YTD
- +15.90%
- 1 year
- +72.75%
- Open
- 7.29
- Prev close
- 7.29
- Mkt cap
- 46.99M
- Vol
- 0
- Avg vol
- 108.25K
- EPS
- -13.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.29
- High
- 7.29
- Forward P/E
- -0.62
- Beta
- 0.22
- Short ratio
- 0.93
- Inst. own
- 63.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 7.44
- 200-d avg
- 7.19
- 1y target
- 13.50
Key statistics
- Market cap
- 46.99M
- Enterprise value
- -91.92M
- Trailing P/E
- 0.00
- Forward P/E
- -0.62
- PEG ratio
- 0.00
- Price / sales
- 6.71
- Price / book
- 0.25
- EPS (TTM)
- -13.12
- Beta
- 0.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 7.00M
- Revenue growth
- 0.00%
- Free cash flow
- -41.50M
- Total cash
- 164.18M
- Total debt
- 17.61M
- Return on equity
- -51.48%
- Shares outstanding
- 7.30M
- Short % of float
- 2.50%
- 50-day average
- 7.44
- 200-day average
- 7.19
Analyst view
Consensus: buy
- Target (low)
- 9.00
- Target (mean)
- 13.50
- Target (high)
- 18.00
- Strong buy0
- Buy2
- Hold4
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -2.76.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -3.03 | -2.78 | +0.25 | +8.25% |
| Aug 13, 2024 | Jun 1, 2024 | -3.20 | -2.80 | +0.40 | +12.50% |
| Aug 13, 2024 | Jun 1, 2024 | -3.20 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -3.40 | -3.00 | +0.40 | +11.76% |
| May 9, 2024 | Mar 1, 2024 | -3.40 | — | — | — |
| Mar 14, 2024 | Dec 1, 2023 | -3.90 | -3.50 | +0.40 | +10.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Dec 2, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Nov 14, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 18, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Oct 14, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Oct 2, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
About Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kezarlifesciences.com
News
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Wednesday
- Stocks That Hit 52-Week Lows On Thursday
Your note
Sign in to keep a note on KZR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FOWLER JOHN FRANKLIN | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 9, 2022 | 436,115 |
| KIRK CHRISTOPHER J | Director | Conversion of Exercise of derivative security | Jul 19, 2023 | 431,348 |
| MORNINGSIDE VENTURE INVESTMENTS, LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 5, 2023 | 5,447,990 |
| SCHILLER MARK C | Officer | Sale | Jul 1, 2024 | 33,007 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Adar1 Capital Management, LLC | 18.34% | 1,338,273 | 8.62M | Sep 29, 2024 |
| Suvretta Capital Management, LLC | 9.82% | 716,759 | 4.62M | Sep 29, 2024 |
| Avidity Partners Management, LP | 6.89% | 502,600 | 3.24M | Sep 29, 2024 |
| Tang Capital Management, LLC | 4.99% | 364,030 | 2.34M | Sep 29, 2024 |
| Vanguard Group Inc | 3.76% | 274,111 | 1.77M | Sep 29, 2024 |
| Affinity Asset Advisors, Llc | 3.44% | 251,178 | 1.62M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.57% | 187,756 | 1.21M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.05% | 76,473 | 492.49K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.49% | 35,834 | 230.77K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 10,810 | 69.62K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 8,522 | 54.88K | Oct 30, 2024 |
| Price (T.Rowe) U.S. Equities Trust | 0.11% | 8,360 | 53.84K | Sep 29, 2024 |